Here in Jakarta on Wednesday, Indofarma President Director Sahat\nSihombing explained Indonesia\u2019s natural wealth must be explored in a\nmore focused manner through sustained research and collaboration between\nthe industry, universities, and research institutions.<\/p>\n
\u201cIndonesia is blessed with extraordinary biodiversity, including\nvarious plants that have the potential to be developed into raw\nmaterials for nature-based medicines. We need to explore the potential\nthrough scientific research, technological innovation, and close\ncollaboration among universities, research institutions, and the\nindustry,\u201d Sihombing said.<\/p>\n
He added the challenge lies not only in identifying the potential of\nnatural materials, but also in ensuring that research findings can be\nsuccessfully processed into products that are safe, high-quality,\neffective, compliant with regulatory requirements, and economically\nvaluable for Indonesia.<\/p>\n
Related news: RI, China launch pharma venture to boost healthcare\nindependence<\/p>\n
In supporting the research translation, Sihombing noted Indofarma\npossesses capacity for the extraction of natural materials, as well as\nproduction facilities for traditional medicines that are certified under\nthe Good Manufacturing Practices for Traditional Medicines (CPOTB)\nstandards.<\/p>\n
He added the capabilities serve as a vital asset for processing\nnatural materials, ranged from extraction to the development of finished\nproducts, such as jamu (traditional herbal medicine), and, provided that\ndevelopment and registration requirements are met, Standardized Herbal\nMedicines and phytopharmaceuticals.<\/p>\n
\u201cThe readiness of these industrial facilities is expected to bridge\nthe gap between research findings and the product development process,\nensuring compliance with quality standards and regulatory requirements,\u201d\nSihombing said.<\/p>\n
Related news: Adaptive regulations key to downstream pharma\ninnovations: BPOM<\/p>\n
Indofarma has signed a Memorandum of Understanding (MoU) with PT\nDanantara Development Management Fund, the Bandung Institute of\nTechnology (ITB), and PT EBM Saintifik dan Teknologi to explore\ncollaborations on the research translation into medicinal plants with\nhigh economic potential.<\/p>\n
Sihombing hopes the collaboration will serve as a foundation for\nsynergy among the parties involved in developing research outcomes,\nevaluating the potential of processing technologies, and exploring\nfunding and investment opportunities.<\/p>\n
Furthermore, the collaboration aims to foster the development of\nnature-based products, advancing them toward commercialization in\naccordance with the respective mandates and capacities of each\nparty.<\/p>\n
In that regard, Sihombing invites all stakeholders to redefine the\nfuture of global health by harnessing the power of Indonesia\u2019s natural\nmedicinal resources.<\/p>\n
Related news: BRIN pushes pharma research collaboration<\/p>\n
Translator: Muhammad Heriyanto, Cindy Frishanti Octavia<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/indofarma-advances-biodiversity-processing-through-research-1793177437", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }